| 61.07 -1.39 (-2.23%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 76.43 | 1-year : | 83.94 |
| Resists | First : | 65.44 | Second : | 71.87 |
| Pivot price | 62.62 |
|||
| Supports | First : | 55.04 | Second : | 45.8 |
| MAs | MA(5) : | 65.57 |
MA(20) : | 62.62 |
| MA(100) : | 76.44 |
MA(250) : | 71.67 |
|
| MACD | MACD : | -0.6 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 53 |
D(3) : | 70.8 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 97.58 | Low : | 47.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ESTA ] has closed above bottom band by 38.8%. Bollinger Bands are 5.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 69.2 - 69.57 | 69.57 - 69.89 |
| Low: | 59.43 - 59.85 | 59.85 - 60.2 |
| Close: | 61.8 - 62.47 | 62.47 - 63.02 |
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Fri, 30 Oct 2026
Establishment Labs Holdings Inc. (ESTA) Seasonal returns chart - Yahoo Finance UK
Fri, 30 Oct 2026
Establishment Labs Holdings Inc. (ESTA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 30 Oct 2026
Establishment Labs Holdings Inc (ESTA) Q3 2026 Earnings Call Highlights: US Revenue Surges 119% ... - Yahoo Finance
Thu, 29 Oct 2026
Establishment Labs Holdings Inc (ESTA) Reports Q3 Revenue of $72 - GuruFocus
Thu, 29 Oct 2026
What Establishment Labs (ESTA) Said on Its Q3 Earnings Call - Yahoo Finance
Thu, 29 Oct 2026
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.953e+007 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 4,400 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.98e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -15.9 % |
| Return on Assets (ttm) | -6.4 % |
| Return on Equity (ttm) | -3.5 % |
| Qtrly Rev. Growth | 2.4582e+008 % |
| Gross Profit (p.s.) | 29.9 |
| Sales Per Share | -165.38 |
| EBITDA (p.s.) | 1.63462e+008 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 63.3 |
| Price to Book value | 0 |
| Price to Sales | -0.37 |
| Price to Cash Flow | 88.67 |
| Dividend | 0 |
| Forward Dividend | 3.98e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|